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SPECIAL COMMUNICATION
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This paper identifies research priorities in evaluating the ways
in which ‘‘genomic medicine’’—the use of genetic information
to prevent and treat disease—may reduce tobacco-related
harm by: (1) assisting more smokers to quit; (2) preventing non-
smokers from beginning to smoke tobacco; and (3) reducing
the harm caused by tobacco smoking. The method proposed to
achieve the first aim is ‘‘pharmacogenetics’’, the use of genetic
information to optimise the selection of smoking-cessation
programmes by screening smokers for polymorphisms that
predict responses to different methods of smoking cessation.
This method competes with the development of more effective
forms of smoking cessation that involve vaccinating smokers
against the effects of nicotine and using new pharmaceuticals
(such as cannabinoid antagonists and nicotine agonists). The
second and third aims are more speculative. They include:
screening the population for genetic susceptibility to nicotine
dependence and intervening (eg, by vaccinating children and
adolescents against the effects of nicotine) to prevent smoking
uptake, and screening the population for genetic susceptibility
to tobacco-related diseases. A framework is described for
future research on these policy options. This includes:
epidemiological modelling and economic evaluation to specify
the conditions under which these strategies are cost-effective;
and social psychological research into the effect of providing
genetic information on smokers’ preparedness to quit, and the
general views of the public on tobacco smoking.
‘‘Genomic medicine’’ is a phrase used to describe the use of
genomic knowledge to improve human health by increasing our
ability to prevent and treat human disease, which it is claimed
will revolutionise healthcare.1 2 ‘‘Predictive genomic medicine’’
involves screening healthy people to identify those who carry
alleles that increase their susceptibility to diseases such as
cancer and heart disease. People found to be at higher genetic
risk of these disorders would be advised to change their
behaviour (eg, stop smoking, exercise or eat a healthier diet) or
be offered drugs or other medical treatment to reduce their
chances of developing these diseases. ‘‘Pharmacogenetics’’ is a
genomic strategy that aims to use genetic information to
identify the type of treatment that will maximise an indivi-
dual’s chances of a good outcome.2
Given the major contribution that tobacco smoking continues
to make to disease burden, and the claims made for genomic
medicine, it is important for the tobacco control field to begin to
explore the ways in which genomic medicine may or may not
contribute to the reduction of tobacco smoking and tobacco-
related disease. This paper outlines a research agenda to
identify the most promising applications of genomic medicine
to tobacco control. It begins with the most plausible and
currently active field of research, the pharmacogenetics of
treating nicotine dependence.3 It assesses this option against
the main competitive strategy, searching for more effective
smoking cessation treatments, and outlines the type of research
required to evaluate its role.
The paper then considers the more speculative predictive use
of genetic information in screening for susceptibility alleles for
nicotine dependence and tobacco-related disease. It says why
this strategy is least likely to be useful. Despite the fact that this
possibility remains speculative, entrepreneurs have begun to
market genetic tests directly to consumers that they claim will
provide people with information about their genetic suscept-
ibility to addiction.4 The tobacco-control field therefore needs to
be ready to explain to policy makers and the general public why
these options are unlikely to deliver the benefits claimed by
their proponents.
THE GENETICS OF TOBACCO SMOKING
Twin studies of cigarette smoking in developed countries
estimate that the heritability of smoking initiation is 50%,5 6
whereas the heritability of nicotine dependence may be as high
as 70%.5 7 Plausible ‘‘candidate genes’’ are present that increase
the risks of nicotine dependence. These are polymorphisms
(variant alleles found in .1% of the population) that affect an
individual’s risk of developing nicotine dependence by affecting
peripheral nicotine metabolism8 and the brain’s response to
nicotine via levels of central dopamine receptors and transpor-
ters, (eg 3 9 10) neurotransmitters implicated in mediating the
rewarding effects of drugs, food and sex in the nucleus
accumbens of the forebrain.11 12
The candidate genes that have been investigated to date have
not been consistently found in all association studies.5 13 This
has led some geneticists to question the value of searching for
addiction susceptibility genes,14 but others15 remain optimistic
that the recent completion of the haplotype map will improve
the efficiency of gene searches and the replicability of results.16
On the available data, the most plausible hypothesis is that the
inheritance of smoking is polygenic—that is, there are multiple
genes of small effect involved.7 10 17 18 Meta-analyses of suscept-
ibility alleles for 55 different medical conditions (including
psychiatric and behavioural disorders) suggest that the suscept-
ibility genes which are replicated only modestly increase the risk—
that is, increase the risk of the disorder 1.2–1.5 times.19 20 These
modest associations have major implications for the plausibility of
predictive genetics, as discussed below.
USING GENETICS AND NEW BIOTECHNOLOGIES TO
IMPROVE SMOKING CESSATION
Assessing the pharmacogenetics of smoking cessation
Current pharmacological aids to smoking cessation either
replace the nicotine delivered by cigarettes (nicotine replace-
ment therapy (NRT))21 or act on central nervous system sites to
Abbreviations: DRD2, dopamine D2 receptor; NRT, nicotine replacement
therapy
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reduce withdrawal symptoms (bupropion) during smoking
cessation.22 These approaches improve on smoking cessation
rates produced by self-quitting and behavioural interven-
tions23 24; they are also cost effective.25 Nevertheless, only a
minority of smokers succeed in quitting using these methods.26
Pharmacogenetics is suggested as a way of improving the
modest success of smoking cessation. Genetic information (eg,
about nicotine metabolism or dopamine response to nicotine)
could be used to match smokers to the treatment most likely to
enable them to quit using buproprion or NRT.3 12 27 A
pharmacogenetic test for nicotine dependence—NicoTest—has
been marketed in the UK via direct to consumer advertising as a
way of helping smokers to decide whether to use NRT or
bupropion in a quit attempt.
The two major questions that arise while assessing nicotine
pharmacogenetics are: (1) is this approach effective—that is, do
the genotypes identified predict differential responses to
treatment? If so, (2) will the additional costs of genetic testing
be justified by the increases in cessation rate produced?28
If we assume that the answer to the first question is positive,
how would we assess the cost-effectiveness of nicotine
pharmacogenetics? We know that the cost-effectiveness of
pharmacogenetic tests is affected by the characteristics of: the
genes being tested, the condition being treated, and the
treatments that genetic tests are being used to select among.28
Among the key characteristics of the gene being tested are its
prevalence in the population of smokers and how well it
predicts differential treatment response. Screening for rare
polymorphisms is not very useful unless they are very strong
predictors of treatment outcome, as a very large number of
people will need to be tested to identify the small number of
people who respond differentially to treatment. The predictive
value of the polymorphisms for the outcome of interest (eg,
differential response to smoking cessation interventions)
reflects the sensitivity and specificity of the genetic test for
the polymorphisms and the penetrance of the gene—that is, the
degree to which people with the polymorphism differ in their
response to treatment from those who do not. A genetic test for
a gene of low prevalence and penetrance is unlikely to be
useful.28 This describes the alleles that have been evaluated in
studies of nicotine pharmacogenetics to date.3
We can specify the type of research required to assess the
cost-effectiveness of nicotine pharmacogenetics using NicoTest
as an example. Nicotest uses the results of a genetic test for a
polymorphism in the dopamine D2 receptor (DRD2) allele to
determine whether a smoker is more likely to quit smoking
using NRT or buproprion (http://www.nicotest.com/). One
could model the cost-effectiveness of NicoTest using empirical
evidence on: the prevalence of the DRD2 polymorphism among
smokers; its predictive value for success in quitting with NRT or
bupropion; the cost charged for the test; epidemiological
models of the tobacco-related mortality and morbidity that
would occur among smokers who continue to smoke versus
those who successfully quit using these methods; and estimates
of the costs of treating tobacco-related disease that have been
averted by successful quitting.
The critical issue in evaluating the cost-effectiveness of NicoTest
is the condition with which we compare its cost-effectiveness. A
comparison condition is required to decide whether the improve-
ment in cessation rate achieved by NicoTest is worth the
additional costs incurred by the genetic testing and counselling
that its use entails.27 28 This will require studies that compare the
cost-effectiveness of NicoTest with simpler and cheaper methods
of treatment selection, such as avoiding matching by offering all
patients the most effective treatment (averaged across geno-
types).7 The critical measure in this case will be the incremental
cost-effectiveness ratio: the ratio of the difference in benefits
between using NicoTest and not matching, divided by the
difference in costs between these two approaches.28
In addition to cost effectiveness, evaluations of NicoTest will
need to consider the social and psychological consequences of
giving smokers information about their genetic susceptibility to
nicotine dependence. The implicit assumption of pharmacoge-
netics is that this information will motivate smokers to use the
treatment provided, but this cannot be simply assumed.29 We need
to investigate the ‘‘folk genetics’’ of nicotine dependence: the
everyday inferences that people in the community draw about the
plasticity of smoking and its amenability to intervention if it is
seen as being in some sense ‘‘genetic’’. Specifically, we need to
discover whether popular simplifications of smoking ‘‘genetics’’
entails a form of genetic reductionism30—namely, the belief that
smoking is a fixed and immutable behaviour that can only be
changed with great difficulty, if at all, by biological interven-
tions.29 31 32 Two studies carried out to date on smokers’ under-
standing of the implications of information about genetic risk for
cessation33 34 suggest that smokers who accept the plausibility of a
genetic contribution to cigarette smoking are less confident about
their self-efficacy in quitting and more likely to see a biological
intervention as required to become abstinent. More work is
required on this issue.
Searching for more effective smoking cessation
treatments
There would be less reason to investigate nicotine pharmaco-
genetics if we could substantially improve the efficacy of
smoking cessation methods. The development of several new
aids to smoking cessation treatment that have recently been
approved or are currently being trialled promises to improve on
the modest efficacy of NRT and bupropion.
One of these new methods that has captured a great deal of
media and popular interest is the ‘‘nicotine vaccine’’. This is an
immunotherapeutic approach to smoking cessation that
induces the immune system to produce antibodies that bind
to nicotine and prevent it from crossing the blood–brain barrier
to act on receptors in the brain.35–37 Animal studies have shown
that attaching nicotine to a suitable antigenic protein35 38 39
produces antibodies that have a high affinity for nicotine and
prevent it from reaching the brain.39 Vaccination of animals
attenuates nicotine effects40 and suppresses dopamine release
in the nucleus accumbens.38 41
At least three biotechnology companies (Cytos (Zurich,
Switzerland), Nabi (Florida, USA) and Xenova (Cambridge,
UK)) are developing a type of nicotine vaccine.42 Successful
phase 1 trial results have been published on one of the
vaccines43 and phase 2 human clinical trials are in progress on
all three vaccines.42 Early reports of abstinence rates at
6 months released by some of these companies44–46 look
promising, but no detailed reports have yet been published in
peer-reviewed journals.
Active vaccination against nicotine could be used to reduce
relapse to smoking in abstinent smokers. Nicotine antibodies
would attenuate the pharmacological effects of nicotine during
the first few months after quitting when most smokers relapse,
thereby reducing the chance that a slip will produce a return to
daily smoking.37 A nicotine vaccine would not be perfectly
effective, as it could be circumvented by increasing the dose of
nicotine. Nonetheless, attenuating the rewarding effects of
nicotine may be enough to reduce relapse rates in smokers by
making a lapse less likely to lead to a return to daily smoking.47
A nicotine vaccine has several potential advantages over NRT
and bupropion. Firstly, it does not require daily dosing: an
active vaccine administered two to four times could produce
immunity that would last for several months.48 Less frequent
dosing should ensure better compliance.37 Secondly, as the
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nicotine antibodies do not act in the brain, they are likely to
have fewer adverse side effects. Finally, a nicotine vaccine can
also be used in combination with bupropion to reduce with-
drawal and depressive symptoms in abstinent smokers.37
The cost-effectiveness of a nicotine vaccine can be evaluated
using an approach similar to that used to model the cost-
effectiveness of NicoTest—that is, by comparing its likely cost
effectiveness with that of the best available current treatment,
bupropion. In the absence of data on efficacy and vaccine costs,
this approach to modelling would involve estimating how much
more effective than bupropion a nicotine vaccine would need to
be, for a given cost, to qualify as a cost-effective smoking
cessation intervention.
Several uncertainties exist about a nicotine vaccine, the
significance of which is more difficult to assess. One such
uncertainty is the effect of public concerns about the safety of
vaccines against childhood infectious diseases49 50 on the
perceived safety and, consequently, on the uptake of a nicotine
vaccine. This issue will need to be explored by assessing the
interest in and attitudes of current smokers towards using a
nicotine vaccine to quit smoking. A second uncertainty arises
from the potential preventive use of nicotine vaccines in
children and adolescents. This possibility (which is discussed
below) may overshadow the more promising use of a vaccine
for smoking cessation in adults.
A third type of uncertainty concerns the challenges that a
nicotine vaccine faces from new pharmaceuticals for smoking
cessation. Specifically, it is uncertain whether competitive nicotine
vaccines will prove to be cost-effective with a nicotine receptor
partial agonist, varenicline,51 52 and rimonabant, a cannabinoid
antagonist that has been approved for the treatment of obesity
and that also shows promise in treating nicotine dependence.26 53
A smoking cessation drug that avoided weight gain would be
enormously attractive to many smokers even if it was no more
effective than current cessation pharmacotherapies.26
Methods have been developed for evaluating the cost-
effectiveness of new pharmaceuticals54 and evidence from such
analyses is routinely required in making decisions on the public
subsidy of new drugs in Australia.55 The research challenge for
the tobacco control community will be adapting these methods
to provide comparable evaluations of the cost effectiveness of
new pharmaceuticals, nicotine vaccines and nicotine pharma-
cogenetics to assist policy makers in deciding which policies are
worthy of support.
USING NEW BIOTECHNOLOGIES TO PREVENT
SMOKING AND SMOKING-RELATED DISEASES
Predictive testing for the genetic risks of nicotine
dependence
If susceptibility genes for nicotine dependence are identified
(possibly as a result of the increased efficiency of gene hunting
made possible by the haplotype map project), then it would be
possible in principle to screen the population for susceptibility
to nicotine dependence and provide preventive behavioural and
pharmacological interventions to people who are at higher
genetic risk.1 The obvious objection is that it is not good public
health policy to encourage people to smoke tobacco, regardless
of their genetic risk. Nonetheless, the idea has a popular appeal
in the media56 and genetic tests are now being marketed for this
purpose in the USA; hence, it is important that the tobacco
control field explains to the community and their political
representatives why it is not good public health policy to screen
the population for genetic susceptibility to nicotine depen-
dence.57
1. Individual alleles that have been identified to date (eg,
DRD2) only weakly predict an increased risk of various
forms of drug dependence (with an average relative risk of
1.45).58
2. Risk prediction for people does not improve a great deal if
we test multiple susceptibility alleles.59 Testing multiple
genetic variants that are individually weak predictors will
improve prediction (eg, if the results of tests of multiple
susceptibility alleles are combined via regression to
produce a risk score60 61). However, in general, the greater
the number of genes that are involved in disease
susceptibility, the less useful most people will find the
information about their genotype. This is because the risk
distribution for multiple alleles (assuming that the risks
are multiplicative) will be approximately log normal.
Consequently, the number of people who have multiple
genes that confer either a very high or a very low risk of
nicotine dependence will be small and most people
screened will prove to be at ‘‘average’’ genetic risk.7 60
3. Given the low prevalence of high-risk combinations of
susceptibility gene variants, a large number of people
would need to be screened to identify the few at highest
risk.62–64 This and the preceding point are illustrated in
Yang et al’s65 simulation of the performance characteristics
of a test that screens for five susceptibility alleles, each
with a relative risk (RR) of disease that ranged from 1.5 to
3.5 and a prevalence in the population between 0.10 and
0.25. These genes were also assumed to interact with a
relatively common environmental exposure (with a pre-
valence of 15%) and an RR of 2. Computer simulations
showed that the prediction of disease risk was substan-
tially improved by testing for the five alleles. For example,
people who screened positively on all five genes had an
81% chance of developing the disease and this increased to
89% if they had been exposed to the risk factor. However,
the number of people who possessed this combination of
genes and environmental exposure was very small: only
3.75 in 100 000 people would have all five susceptibility
alleles and ,1 (0.6) in 100 000 would have the five alleles
and the environmental exposure. Hence, 250 000 people
would need to be screened to identify 1 person who had
.80% chance, and 1266 people would need to be screened
to identify one person with .50% chance, of developing
the disease.
4. Screening is ethically justifiable only if there is an effective
intervention to prevent the disorder in those who are
identified as being at increased risk.59 64 66 No interventions
are seen at present, apart from advice to ‘‘avoid smoking’’,
which is good advice regardless of one’s genetic suscept-
ibility to nicotine dependence. The possibility of preventive
vaccination is discussed below.
5. As was the case with nicotine pharmacogenetics, we also
need to know what the psychological effects will be of
giving people information about their genetic risk of
nicotine dependence. Unintended adverse effects could
occur—for example, if telling adolescents about their
susceptibility to nicotine dependence increased their
curiosity to try smoking or reduced their likelihood of
later attempting to quit if they did smoke tobacco. These
possibilities also need to be explored in studies of the
psychological effect of providing genetic information.29
6. We would need to explore the effects of providing genetic
information about nicotine dependence on health or life
insurance, and the possible social stigmatisation of those
who are identified as being at increased ‘‘genetic risk’’.
The social stigmatisation could arise because of plei-
tropy—the fact that the genes that predict an increased
risk of nicotine dependence may also predict an increased
risk of other more stigmatised disorders. This is the case
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with the DRD2 allele that is used in NicoTest and
marketed as an addiction susceptibility genetic test. It is
also associated (albeit modestly) with an increased risk of
alcohol dependence, compulsive gambling, and addiction
to heroin and cocaine.58 67
Screening for genetic susceptibil ity to tobacco-related
diseases
Genetic factors appear to play a part in susceptibility to some
types of cancer, including lung cancer,68 although there is
disagreement about how large a part they play.69–72
Polymorphisms may also affect the likelihood of smokers
developing heart disease73 and chronic obstructive lung
disease.74 These findings raise a possibility that ambivalent
smokers may find attractive—namely, that they could be
screened for susceptibility genes that predicted an increased
risk of smoking-related diseases if they smoked and that, if they
were at low genetic risk, they could continue to smoke with
impunity.75
On the basis of the available evidence, this option is even
more impractical than screening for genetic susceptibility to
nicotine dependence for reasons that need to be clearly
communicated to the public. Firstly, since multiple genes are
probably involved in susceptibility to tobacco-related diseases,
the ability to predict disease risk may not improve on predicting
risk from being a smoker. Secondly, cigarette smoking causes
multiple diseases, the most common being lung and other
cancers, heart disease and chronic obstructive lung disease. This
means that predicting the genetic risk of developing even only
the most common tobacco-related diseases would involve
testing individuals for a large number of polymorphisms.
Thirdly, very few smokers would be at low risk of developing
all smoking-related diseases. Indeed, most smokers would be at
increased genetic risk for at least one smoking-related disease,75
as can be illustrated by some simple calculations. Let us assume
that there are only six susceptibility alleles (each with an RR of
1.5, a prevalence of 10% and with multiplicative risks) for each
of the five major tobacco-related diseases (lung cancer,
coronary heart disease, chronic lung disease, other cancers
and stroke). As per these assumptions, only 3% of smokers
would be at low risk of developing all five diseases; the
remainder would have an increased risk of developing at least
one of the diseases.
Preventive uses of a nicotine vaccine
The term nicotine vaccine suggests the possibility that children
can be given lifelong immunity to smoking that may prompt
parents to vaccinate their children.76 As minors, children would
not be legally able to consent to vaccination, but some say that
as parents already make choices for their children that affect
their lives (eg, their diet and education), vaccination against
drugs is just another decision that parents should be able to
make on behalf of their children.76 These are thorny ethical
issues.77
Even if we set the ethical issues aside, there are good
practical reasons why we should not rush into using a nicotine
vaccine to prevent children from smoking. Firstly, the limited
period of protection provided by existing vaccines would require
booster injections, perhaps every 2–3 months throughout
adolescence.48 Secondly, the vaccine can be circumvented by
using larger than usual doses of nicotine. Thirdly, vaccination
could also have counterproductive effects if adolescents were
tempted to test the vaccine’s efficacy by smoking at a higher
rate. Fourthly, it would be expensive to universally vaccinate
children using a vaccine that would probably have modest
efficacy. This makes universal vaccination unlikely to be
publicly funded.
It would be less expensive to vaccinate only young people
who were at increased ‘‘genetic risk’’ of smoking tobacco,
which may make predictive genetics and nicotine vaccines seem
a good combination. The feasibility of this approach looks poor
given (1) the poor predictive validity of genetic screening for
nicotine dependence (as outlined above); (2) the probable
modest preventive efficacy of a nicotine vaccine; and (3) the
possibility of unintended adverse effects of vaccination, such as
stigmatisation of those who screen positive and possible
discrimination against those who were vaccinated by life or
health insurance companies.
SUMMARY
Given the promises made for genomic medicine, we need
detailed analyses of the feasibility, likely effectiveness and cost-
effectiveness, and the ethical and policy issues raised in using
information on genetic risks of nicotine dependence and
tobacco-related disease to increase smoking cessation or reduce
tobacco-related disease. The following conjectures based on the
available data need to be tested in more detailed analyses as
better data come to hand.
New genetic and immunological biotechnologies have the
potential to increase the modest success rates of current
smoking cessation programmes. On the basis of available data,
new pharmacological cessation treatments and nicotine vac-
cines look more promising than screening smokers for
polymorphisms that predict responses to existing, modestly
effective pharmacological treatments for smoking cessation.
Better empirical data and epidemiological and economic
modelling of the comparative cost effectiveness of these
approaches is needed to assist policy makers in deciding which
of these approaches to support. We also need to evaluate the
effects of providing genetic risk information on self-efficacy
and beliefs of smokers that may affect their willingness to quit
smoking and the interest of current smokers in using nicotine
vaccines for smoking cessation.
The preventive use of biotechnologies—screening the popu-
lation for genetic susceptibility to nicotine dependence, screen-
ing smokers for polymorphisms that predict increased
susceptibility to tobacco-related diseases, and vaccinating
non-smoking children against the effects of nicotine—are more
speculative policy options. Given the current data, their likely
efficacy and cost-effectiveness look doubtful. Population
screening for multiple susceptibility genes for nicotine depen-
dence is a poor public policy because there is no good reason for
anyone to smoke tobacco. It also faces major technical
challenges—namely, the polymorphisms identified to date
weakly predict the risk for most people; it will be costly to
screen large numbers of people to identify the small number at
highest risk; there are no effective interventions for those
identified as at risk; and screening may have counterproductive
What this paper adds
N Twin studies have indicated that genes contribute to
nicotine dependence. These may include genes that affect
nicotine metabolism and the effects of nicotine on brain
neurotransmitters.
N This paper describes the potential therapeutic and
preventive applications of recent research on the genetics
and neurobiology of nicotine dependence.
N It also identifies research priorities in evaluating their cost
effectiveness, and the social and ethical issues that their
use may raise.
56 Hall
www.tobaccocontrol.com
 on 12 February 2007 tc.bmj.comDownloaded from 
effects. The impracticality of population screening for genes
that predict low risk of smokers developing smoking-related
diseases is increased by the large number of susceptibility genes
that will need to be screened for and the very small chance that
many smokers will be at low risk of developing all of the major
diseases caused by tobacco smoking.
Even if these new technologies prove successful, it will
remain cheaper and more efficient to implement them in a
tobacco policy setting in which we continue to use taxation and
other policies to discourage the whole population from smoking
tobacco.78 79 A challenging task for social science research will
be assessing the effects that these genetic technologies may
have on public understanding of tobacco use and public support
for tobacco control policies.80
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